Results 71 to 80 of about 1,089 (172)

Structural determinants influencing halogen bonding: a case study on azinesulfonamide analogs of aripiprazole as 5-HT1A, 5-HT7, and D2 receptor ligands

open access: yesChemistry Central Journal, 2018
A series of azinesulfonamide derivatives of long-chain arylpiperazines with variable-length alkylene spacers between sulfonamide and 4-arylpiperazine moiety is designed, synthesized, and biologically evaluated.
Krzysztof Marciniec   +8 more
doaj   +1 more source

Coumarin-piperazine derivatives as biologically active compounds

open access: yesSaudi Pharmaceutical Journal, 2020
A number of psychiatric disorders, including anxiety, schizophrenia, Parkinson’s disease, depression and others CNS diseases are known to induce defects in the function of neural pathways sustained by the neurotransmitters, like dopamine and serotonin. N-
Kinga Ostrowska
doaj   +1 more source

Ionization constants and partition coefficients of 1-arylpiperazine derivatives

open access: yesJournal of Pharmacy and Pharmacology, 1985
AbstractThe ionization constant (pKa and liposolubilities (log P) of fourteen 1-arylpiperazines were determined by n-octanol/buffer partition. pKa varied little across the entire series. Log P values ranged from less than 1 to about 2 for the highly lipophilic derivatives of the preset series.
S, Caccia, M H, Fong, R, Urso
openaire   +2 more sources

The Structure–Antimicrobial Activity Relationships of a Promising Class of the Compounds Containing the N-Arylpiperazine Scaffold

open access: yesMolecules, 2016
This research was focused on in silico characterization and in vitro biological testing of the series of the compounds carrying a N-arylpiperazine moiety.
Ivan Malík   +9 more
doaj   +1 more source

Arylpiperazine Dopamineric Ligands Protect Neuroblastoma Cells from Nitric Oxide (NO)-Induced Mitochondrial Damage and Apoptosis

open access: yes, 2012
The protective ability of novel arylpiperazine-based dopaminergic ligands against nitric oxide (NO)-mediated neurotoxicity is investigated. The most potent neuroprotective arylpiperazine identified during the study was N-{4-[2-(4-phenyl-piperazin-1-yl ...
Trajković, Vladimir   +24 more
core   +1 more source

Chalcone–Arylpiperazine Hybrids as Potential Antianxiety Agents: Synthesis, Biological Evaluation, Molecular Modeling, and Network Pharmacology Studies

open access: yes
Introduction: Anxiety disorders are among the most prevalent mental health conditions, yet recent drug development has yielded few novel antianxiety agents.
Nitin Sati   +4 more
core   +1 more source

Synthesis, computational and pharmacological evaluation of novel N-{4-[2-(4-aryl-piperazin-1-yl)ethyl]phenyl}-arylamides [PDF]

open access: yesJournal of the Serbian Chemical Society
Serotonin, or 5-hydroxytryptamine (5-HT), is a biogenic amine most noted as a neurotransmitter, an activator of the utmost subtype family of G-protein- coupled receptors (GPCR). Drugs targeting 5-HT1A and other 5-HT receptors treat central nervous system
Andrić Deana B.   +6 more
doaj   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2018
In our endeavour towards the development of effective anticancer therapeutics, a novel series of isoxazole-piperazine hybrids were synthesized and evaluated for their cytotoxic activities against human liver (Huh7 and Mahlavu) and breast (MCF-7) cancer ...
Burcu Çalışkan   +5 more
doaj   +1 more source

New Imide 5-HT1A Receptor Ligands – Modification of Terminal Fragment Geometry

open access: yesMolecules, 2004
Two sets of new o-methoxyphenylpiperazine (MPP; series a) and 1,2,3,4-tetrahydroisoquinoline (THIQ; series b) derivatives, containing various imide moietiesderived from NAN190, were synthesized and evaluated in vitro for their ability to bind tothe ...
Ryszard Bugno   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy